Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
Want to see QNRX full AI Analyst Report?
Total Valuation
Quoin Pharmaceuticals has a market cap or net worth of $8.89M. The enterprise value is -$3.81B.
Market Cap$8.89M
Enterprise Value-$3.81B
Share Statistics
Quoin Pharmaceuticals has 1,803,626 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,803,626
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Quoin Pharmaceuticals’s return on equity (ROE) is -1.20K and return on invested capital (ROIC) is -110.62%.
Return on Equity (ROE)-1.20K
Return on Assets (ROA)-775.10
Return on Invested Capital (ROIC)-110.62%
Return on Capital Employed (ROCE)-1.11
Revenue Per Employee0.00
Profits Per Employee-5.27B
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Quoin Pharmaceuticals is ―. Quoin Pharmaceuticals’s PEG ratio is >-0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio1.17
Price to Fair Value1.17
Price to FCF>-0.01
Price to Operating Cash Flow-0.47
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Quoin Pharmaceuticals had revenue of 0.00 and earned -15.80B in profits. Earnings per share was -14.80K.
Revenue0.00
Gross Profit-100.79K
Operating Income-16.42M
Pretax Income-15.93M
Net Income-15.80B
EBITDA-16.32M
Earnings Per Share (EPS)-14.80K
Cash Flow
In the last 12 months, operating cash flow was -13.59M and capital expenditures 4.00, giving a free cash flow of -13.59M billion.
Operating Cash Flow-13.59M
Free Cash Flow-13.59M
Free Cash Flow per Share-7.53
Dividends & Yields
Quoin Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.03
52-Week Price Change-12.41%
50-Day Moving Average7.71
200-Day Moving Average9.94
Relative Strength Index (RSI)43.91
Average Volume (3m)629.04K
Important Dates
Quoin Pharmaceuticals upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Quoin Pharmaceuticals as a current ratio of 3.61, with Debt / Equity ratio of 0.00%
Current Ratio3.61
Quick Ratio3.61
Debt to Market Cap0.00
Net Debt to EBITDA233.96
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Quoin Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Quoin Pharmaceuticals EV to EBITDA ratio is 233.02, with an EV/FCF ratio of 0.28.
EV to Sales0.00
EV to EBITDA233.02
EV to Free Cash Flow0.28
EV to Operating Cash Flow0.28
Balance Sheet
Quoin Pharmaceuticals has $3.82B in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.82B billion.
Cash & Marketable Securities$3.82B
Total Debt$0.00
Net Cash$3.82B
Net Cash Per Share$2.12K
Tangible Book Value Per Share-$346.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Quoin Pharmaceuticals is $37.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$37.50
Price Target Upside219.97% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-464.26%